<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01861080</url>
  </required_header>
  <id_info>
    <org_study_id>2012-005</org_study_id>
    <nct_id>NCT01861080</nct_id>
  </id_info>
  <brief_title>Korean Registry of Target Organ Damages in Hypertension</brief_title>
  <acronym>KorHR</acronym>
  <official_title>Observational Study of Clinical Characteristics and Prognostic Factors of Korean Hypertensives</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dongtan Sacred Heart Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dongtan Sacred Heart Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to know prevalence of clinical or subclinical target organ
      damages in Korea hypertensives by constructing nationwide hypertension registry. We will
      register 5000 consecutive patients with incident hypertension at 20 major university
      hospitals in South Korea. We will investigate clinical/subclinical target organ damages,
      renin/aldosterone level and cardiovascular events in each patient.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: the exact prevalence of target organ damages in Korean hypertensives are unknown.

      Study Objective: to investigate the prevalence of target organ damages in Korean patients
      with incident hypertension.

      Study Design: prospective, multi-center and observational study

      Study Populaton: approximately 5000 consecutive patients with incident hypertension, who
      visited outpatients clinics and agreed to participate in the registry

      Primary outcome

        -  Subclinical organ damages

             1. left ventricular hypertrophy on electrocardiogram or echocardiography

             2. increased intima media thickness of carotid artery (&gt; 0.9 mm) or plaque

             3. increased pulse wave velocity (&gt; 12 m/s)

             4. low estimated glomerular filtration rate (&lt; 60 ml/min/1.73 m2) or creatinine
                clearance (&lt;60 ml/min)

        -  Established CV or renal disease

             1. cerebrovascular disease: ischemic stroke; cerebral stroke; transient ischemic
                attack

             2. Heart disease: myocardial infarction; angina; coronary revascularization; heart
                failure

             3. Renal disease: diabetic retinopathy; serum creatinine M &gt; 133, W &gt; 124 mmol/L;
                proteinuria &gt; 300 mg/24 hr

             4. Peripheral artery disease

             5. Advanced retinopathy: hemorrhage or exudates, papilledema
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>36 Months</target_duration>
  <primary_outcome>
    <measure>left ventricular hypertrophy</measure>
    <time_frame>at enrollment</time_frame>
    <description>left ventricular hypertrophy on electrocardiogram or echocardiography Sokolow-Lyon &gt; 38 mm; left ventricular mass index male &gt;= 125 g/m2, female &gt;=110 g/m2)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intima media thickness of carotid artery</measure>
    <time_frame>at enrollment</time_frame>
    <description>increased intima media thickness of carotid artery (&gt; 0.9 mm) or presence of plaque</description>
  </primary_outcome>
  <primary_outcome>
    <measure>pulse wave velocity</measure>
    <time_frame>at enrollment</time_frame>
    <description>increased pulse wave velocity (&gt; 12 m/s)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>kidney function</measure>
    <time_frame>at enrollment</time_frame>
    <description>low estimated glomerular filtration rate (&lt; 60 ml/min/1.73 m2) or creatinine clearance (&lt; 60 ml/min)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>cerebrovascular accident</measure>
    <time_frame>at enrollment</time_frame>
    <description>ischemic stroke, cerebral hemorrhage, or transient ischemic attack confirmed by a neurologist</description>
  </primary_outcome>
  <primary_outcome>
    <measure>renal disease</measure>
    <time_frame>at enrollment</time_frame>
    <description>serum creatinine male &gt; 1.5 mg/dl, female &gt; 1.4 mg/dl; proteinuria &gt; 300 mg/24hr</description>
  </primary_outcome>
  <primary_outcome>
    <measure>peripheral artery disease</measure>
    <time_frame>at enrollment</time_frame>
    <description>ankle to brachial blood pressure ratio &lt; 0.9</description>
  </primary_outcome>
  <primary_outcome>
    <measure>retinopathy</measure>
    <time_frame>at enrollment</time_frame>
    <description>retinal hemorrhage or exudate, papilledema confirmed by an ophthalmologist</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hypertension</measure>
    <time_frame>at enrollment</time_frame>
    <description>high blood pressure confirmed by ambulatory blood pressure monitoring (24hr average systolic blood pressure &gt;=135 mm Hg, diastolic blood pressure &gt;= 85 mm Hg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyslipidemia</measure>
    <time_frame>at enrollment</time_frame>
    <description>total cholesterol 190 mg/dl or LDL &gt; 115 mg/dl, HDL male &lt; 40 mg/dl, female &lt; 46 mg/dl or triglyceride &gt; 150 mg/dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>abnormal fasting plasma glucose</measure>
    <time_frame>at enrollment</time_frame>
    <description>abnormal fasting plasma glucose (102-125 mg/dl)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>abdominal obesity</measure>
    <time_frame>at enrollment</time_frame>
    <description>waist circumference male &gt; 102 cm, female &gt; 88 cm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>diabetes mellitus</measure>
    <time_frame>at enrollment</time_frame>
    <description>fasting plasma glucose &gt;= 126 mg/dl; postload plasma glucose &gt; 198 mg/dl</description>
  </secondary_outcome>
  <other_outcome>
    <measure>major cardiovascular events</measure>
    <time_frame>after follow-up period of 36 months</time_frame>
    <description>death, stroke, myocardial infarction and heart failure(confirmed by a cardiologist)</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>incident hypertensives</arm_group_label>
    <description>Inclusion Criteria:
age≧30years
primary incident hypertension
signed informed consent</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Korean patients with incident hypertensive, who visited university hospital
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age≧30years

          -  primary incident hypertension

          -  singed informed consent

        Exclusion Criteria:

          -  participated in other clinical trials
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyu-Hyung Ryu, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dongtan Sacred Heart Hospital, Hallym University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kyu-Hyung Ryu, MD, PhD</last_name>
    <phone>+82-31-8086-2827</phone>
    <email>khryumd@hanmail.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Suk-Won Choi, MD</last_name>
    <phone>+82-31-8086-2541</phone>
    <email>swchoi97@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hallym University Dongtan Sacred Heart Hospital,</name>
      <address>
        <city>Hwaseong</city>
        <state>Gyeonggido</state>
        <zip>445-170</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyu-Hyung Ryu, MD, PhD</last_name>
      <phone>+82-31-8086-2827</phone>
      <email>khryumd@hanmail.net</email>
    </contact>
    <contact_backup>
      <last_name>Suk-Won Choi, MD</last_name>
      <phone>+82-31-8086-2538</phone>
      <email>swchoi97@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Kyu-Hyung Ryu, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2013</study_first_submitted>
  <study_first_submitted_qc>May 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 23, 2013</study_first_posted>
  <last_update_submitted>August 29, 2016</last_update_submitted>
  <last_update_submitted_qc>August 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dongtan Sacred Heart Hospital</investigator_affiliation>
    <investigator_full_name>Suk Won Choi</investigator_full_name>
    <investigator_title>Kyu-Hyung Ryu, M.D., Professor</investigator_title>
  </responsible_party>
  <keyword>target organ damage</keyword>
  <keyword>incident hypertension</keyword>
  <keyword>cohort</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

